BEFORE THE

INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

SPECIAL MEETING

LOCATION: AS INDICATED ON THE AGENDA

DATE: TUESDAY, MAY 25, 2010 8 A.M.

REPORTER: BETH C. DRAIN, CSR CSR. NO. 7152

BRS FILE NO.: 87444

INDEX

1. CALL TO ORDER32. ROLL CALL33. CONSIDERATION OF UPDATE AND POSITION ON SB 1064 (ALQUIST).64. ADDITIONAL ITEM:26CONSIDERATION OF FUNDING FOR PARTICIPATION IN THE ISSCR ANNUAL MEETING FOR PATIENT ADVOCATES, CIRM TRAINING GRANTS PARTICIPANTS (CIRM SCHOLARS), BRIDGES TO STEM CELL RESEARCH PARTICIPANTS (MASTERS)	
 3. CONSIDERATION OF UPDATE AND 6 POSITION ON SB 1064 (ALQUIST). 4. ADDITIONAL ITEM: 26 CONSIDERATION OF FUNDING FOR PARTICIPATION IN THE ISSCR ANNUAL MEETING FOR PATIENT ADVOCATES, CIRM TRAINING GRANTS PARTICIPANTS (CIRM SCHOLARS), BRIDGES TO STEM CELL RESEARCH PARTICIPANTS (MASTERS 	
POSITION ON SB 1064 (ALQUIST). 4. ADDITIONAL ITEM: 26 CONSIDERATION OF FUNDING FOR PARTICIPATION IN THE ISSCR ANNUAL MEETING FOR PATIENT ADVOCATES, CIRM TRAINING GRANTS PARTICIPANTS (CIRM SCHOLARS), BRIDGES TO STEM CELL RESEARCH PARTICIPANTS (MASTERS	
CONSIDERATION OF FUNDING FOR PARTICIPATION IN THE ISSCR ANNUAL MEETING FOR PATIENT ADVOCATES, CIRM TRAINING GRANTS PARTICIPANTS (CIRM SCHOLARS), BRIDGES TO STEM CELL RESEARCH PARTICIPANTS (MASTERS	
ISSCR ANNUAL MEETING FOR PATIENT ADVOCATES, CIRM TRAINING GRANTS PARTICIPANTS (CIRM SCHOLARS), BRIDGES TO STEM CELL RESEARCH PARTICIPANTS (MASTERS	
DEGREE CANDIDATES) AND RESEARCHERS ON CIRM-FUNDED GRANTS (POST-DOC RESEARCHERS AND GRADUATE DEGREE CANDIDATES), RESTRICTED TO APPLICANTS NOT ALREADY REGISTERED	
PUBLIC COMMENT NONE	
2	

	BARRISTERS' REPORTING SERVICE
1	TUESDAY, MAY 25, 2010
2	8 A.M.
3	
4	MS. KING: OKAY. THANK YOU, EVERYBODY,
5	FOR JOINING THIS MORNING. THIS IS MELISSA IN SAN
6	FRANCISCO, AND I AM GOING TO CALL THE ROLL. I KNOW
7	I HAVE DONALD DAFOE FOR RICARDO AZZIZ, CORRECT?
8	DR. DAFOE: YES, CORRECT.
9	MS. KING: ROBERT BIRGENEAU. FLOYD BLOOM.
10	DR. BLOOM: HERE.
11	MS. KING: DAVID BRENNER. WILLIAM BRODY.
12	DR. BRODY: HERE.
13	MS. KING: JACOB LEVIN FOR SUSAN BRYANT.
14	DR. LEVIN: HERE.
15	MS. KING: MARCY FEIT. MICHAEL FRIEDMAN.
16	LEEZA GIBBONS.
17	MS. GIBBONS: HERE.
18	MS. KING: MICHAEL GOLDBERG. SAM HAWGOOD.
19	BOB KLEIN. SHERRY LANSING. GERALD LEVEY.
20	DR. LEVEY: HERE.
21	MS. KING: TED LOVE.
22	DR. LOVE: HERE.
23	MS. KING: ED PENHOET.
24	DR. PENHOET: HERE.
25	MS. KING: PHIL PIZZO. CLAIRE POMEROY.
	3

1	FRANCISCO PRIETO. CARMEN PULIAFITO. ROBERT QUINT.
2	JEANNIE FONTANA FOR JOHN REED.
3	DR. FONTANA: HERE.
4	MS. KING: DUANE ROTH.
5	MR. ROTH: HERE.
6	MS. KING: JOAN SAMUELSON. DAVID
7	SERRANO-SEWELL.
8	MR. SERRANO-SEWELL: HERE.
9	MS. KING: JEFF SHEEHY.
10	MR. SHEEHY: HERE.
11	MS. KING: JON SHESTACK.
12	MR. SHESTACK: HERE.
13	MS. KING: OSWALD STEWARD. AND ART
14	TORRES.
15	MR. TORRES: HERE.
16	MS. KING: ALL RIGHT. SO WE DON'T QUITE
17	HAVE A QUORUM, SENATOR TORRES, BUT I SUGGEST WE GET
18	STARTED AND MAYBE
19	MR. TORRES: I THOUGHT THIS WAS A BOARD
20	MEETING.
21	MS. KING: RIGHT. BUT I'M ASKING YOU AS
22	VICE CHAIR, WE DON'T YET HAVE OUR CHAIR, IF YOU
23	WOULDN'T MIND.
24	MR. TORRES: I THINK BOB JUST GOT ON.
25	MS. KING: WHO JUST JOINED? HOW ABOUT,
	4

1	MR. HARRISON, COULD YOU PLEASE WALK US THROUGH
2	MR. TORRES: NO. NO. NO. HAVE WE MADE
3	AND ATTEMPT TO GET BOB ON THE LINE?
4	MS. KING: WE HAVE SEVERAL TIMES.
5	MR. TORRES: OKAY. AND WHAT TIME DO WE
6	HAVE? LET'S WAIT A FEW MINUTES.
7	MS. KING: SO THANK YOU AGAIN TO EVERYBODY
8	WHO'S ON THE PHONE. WE'RE GOING TO GIVE OTHERS A
9	COUPLE MORE MINUTES TO JOIN THE CALL AS WE HAVE BEEN
10	DOING FOR A FEW MINUTES ALREADY. SO THANK YOU ALL
11	FOR YOUR PATIENCE.
12	(PAUSE IN PROCEEDINGS.)
13	VICE CHAIRMAN TORRES: THIS IS ART TORRES.
14	I'M GOING TO START THE MEETING WHILE WE'RE WAITING
15	FOR BOB TO GET ON THE PHONE. I WANT TO THANK, FIRST
16	OF ALL, THE PARTICIPANTS IN THIS LEGISLATIVE
17	APPROACH THAT WE HAVE TRIED TO TAKE. FIRST OF ALL,
18	I WANT TO THANK DR. ALAN TROUNSON, WHO'S WITH US;
19	BOB KLEIN, DUANE ROTH, WHO WAS PIVOTAL IN OUR
20	NEGOTIATIONS, AND OUR TWO EXCELLENT NEGOTIATORS,
21	MR. JAMES HARRISON AND MR. SCOTT TOCHER AND ALSO THE
22	INPUT OF ELONA BAUM AND JOHN ROBSON. AND OBVIOUSLY
23	BOB KLEIN WHO WAS INSTRUMENTAL AT THE OUTSET OF
24	THESE NEGOTIATIONS.
25	I ALSO WANT TO GIVE A SPECIAL THANKS TO
	5
	1072 BRISTOL STREET COSTA MESA CALLEORNIA 92626

SENATOR ELAINE ALQUIST AND HER STAFF, TO SENATOR
DARRELL STEINBERG, WHO IS PRESIDENT PRO TEM OF THE
SENATE, WHO BROUGHT US TOGETHER INITIALLY A FEW
WEEKS AGO TO HELP FERRET OUT A COMPROMISE, TO
SENATOR DEAN FLORES AND HIS STAFF, WHO WAS VERY,
VERY HELPFUL TO US IN WORKING WITH SENATOR STEINBERG
AND WITH SENATOR ALQUIST AND WITH SENATOR KEHOE, WHO
IS CHAIR OF THE APPROPRIATIONS COMMITTEE, AND HER
STAFF AS WELL.
DUANE WAS VERY INSTRUMENTAL IN HAVING
EXCELLENT CONVERSATIONS WITH SENATOR KEHOE AND HER
STAFF. AND I BELIEVE THAT WE HAVE COME TOGETHER
WITH A COMPROMISE THAT WE WANTED TO PRESENT TO THE
BOARD FOR OUR SUPPORT AS THIS LEGISLATION MOVES
THROUGH THE PROCESS.
SO I WANT TO TURN IT OVER NOW TO JAMES
HARRISON WHO WILL GO OVER THE POINTS OF THE
LEGISLATION, AND THEN WE CAN GET INTO A DISCUSSION.
JAMES.
MR. HARRISON: GOOD MORNING, EVERYONE. AS
YOU MAY RECALL, SB 1064 BEGAN AS A RATHER BROAD
APPROACH AT AMENDING A VARIETY OF PROVISIONS OF PROP
71. THROUGH OUR NEGOTIATION, WE ARRIVED AT A
COMPROMISE THAT IS SIGNIFICANTLY NARROWER IN SCOPE
THAN WHAT THE BILL BEGAN AS. AND IN PARTICULAR, THE
6

6

1	BILL DOES NOT ADDRESS A NUMBER OF PROVISIONS THAT
2	HAD EARLIER BEEN INCLUDED, INCLUDING MODIFYING THE
3	TERMS OF THE CHAIR AND VICE CHAIR, CODIFYING CALRX
4	PRICING WHICH IS PART OF OUR IP REGULATIONS,
5	EXPANDING THE JURISDICTION OF CITIZENS FINANCIAL
6	ACCOUNTABILITY OVERSIGHT COMMITTEE, MODIFYING THE
7	DUTIES OF THE CHAIR AND THE PRESIDENT, ELIMINATING
8	THE PREAPPLICATION PROCESS, AND INCLUDING A
9	DEFINITION OF ADMINISTRATIVE COSTS. ALL OF THOSE
10	TOPICS ARE NOW OFF THE TABLE AND OUTSIDE THE SCOPE
11	OF THE BILL.
12	LET ME BRIEFLY DESCRIBE WHAT SB 1064 WOULD
13	DO IN ITS CURRENT FORM. FIRST, IT WOULD REMOVE THE
14	50-EMPLOYEE CAP UNDER WHICH CIRM CURRENTLY OPERATES,
15	BUT CONTINUE TO REQUIRE THE AGENCY TO OPERATE WITHIN
16	THE 6-PERCENT OVERALL CAP OF ITS ADMINISTRATIVE
17	EXPENDITURES.
18	SECOND, IT WOULD AUTHORIZE THE BOARD TO
19	SET A DAILY COMPENSATION RATE AS OPPOSED TO A PER
20	DIEM FOR THE PATIENT ADVOCATES ON THE BOARD WHO
21	SERVE AS MEMBERS OF THE WORKING GROUP. CURRENTLY
22	THEY ARE ENTITLED TO A PER DIEM OF 116 PER DAY FOR
23	THE MANY HOURS OF WORK THEY PUT INTO THEIR EFFORTS
24	ON THE WORKING GROUPS.
25	THIRD, THE BILL WOULD REQUIRE THAT CIRM'S
	7
-	

1	INTELLECTUAL PROPERTY REGULATIONS INCLUDE A
2	REQUIREMENT THAT GRANTEES AND EXCLUSIVE LICENSEES
3	SUBMIT A PLAN TO CIRM TO AFFORD ACCESS TO A DRUG
4	THAT IS IN WHOLE OR IN PART THE RESULT OF
5	CIRM-FUNDED RESEARCH TO CALIFORNIANS WHO HAVE NO
6	OTHER MEANS TO PURCHASE THE DRUG. LIKE OUR CURRENT
7	REGULATIONS, WHICH INCLUDE THE REQUIREMENT, THE PLAN
8	WOULD HAVE TO BE CONSISTENT WITH INDUSTRY STANDARDS
9	AT THE TIME OF COMMERCIALIZATION IN CALIFORNIA,
10	ACCOUNTING FOR THE SIZE OF THE MARKET FOR THE DRUG
11	AND THE RESOURCES OF THE GRANTEE OR EXCLUSIVE
12	LICENSEE.
13	IMPORTANTLY, THE BOARD WOULD RETAIN THE
14	AUTHORITY TO IMPLEMENT THIS REQUIREMENT THROUGH
15	REGULATIONS AND ALSO TO GRANT A WAIVER TO THE ACCESS
16	PLAN REQUIREMENT IF THE BOARD WERE TO DETERMINE THAT
17	IN THE ABSENCE OF A WAIVER DEVELOPMENT AND BROAD
18	DELIVERY OF THE DRUG WOULD BE UNREASONABLY HINDERED
19	OR THAT A WAIVER WOULD PROVIDE BENEFITS THAT EQUAL
20	OR EXCEED THE BENEFITS THAT WOULD OTHERWISE FLOW
21	FROM THE ACCESS PLAN. SO THE IMPORTANT THING ABOUT
22	THIS PARTICULAR PROVISION, THOUGH IT CODIFIES PART
23	OF OUR REGULATIONS, IS THAT IT MAINTAINS SIGNIFICANT
24	FLEXIBILITY FOR THE BOARD GOING FORWARD.
25	THE BILL WOULD ALSO CODIFY CIRM'S CURRENT
	8

8

1	REVENUE SHARING REQUIREMENTS IN LARGE PART. IT
2	WOULD REQUIRE THAT OUR IP REGULATIONS INCLUDE A
3	REQUIREMENT THAT CIRM'S GRANTEES SHARE A FRACTION OF
4	THE REVENUES THEY RECEIVE FROM LICENSING OR
5	SELF-COMMERCIALIZING AN INVENTION OR TECHNOLOGY THAT
6	ARISES FROM CIRM-FUNDED RESEARCH. AND IT WOULD
7	REQUIRE THAT THOSE FUNDS GO TO THE STATE GENERAL
8	FUND. IT WOULD ALSO IN LARGE PART, AS I SAID,
9	CODIFY OUR EXISTING FORMULAS. HOWEVER, IT WOULD
10	PROVIDE THE BOARD WITH CONTINUED FLEXIBILITY TO
11	MODIFY THOSE FORMULAS IN THE FUTURE IF THE BOARD
12	DETERMINES IT'S NECESSARY TO RESTRIKE THE BALANCE.
13	AS YOU RECALL, PROP 71 REQUIRES THAT THE
14	IP REGULATIONS BALANCE THE INTEREST OF THE STATE IN
15	GETTING A RETURN ON ITS INVESTMENT WITH THE NEED TO
16	ENSURE THAT ESSENTIAL MEDICAL RESEARCH, INCLUDING
17	THERAPY DEVELOPMENT AND THE BROAD DELIVERY OF
18	THERAPIES TO PATIENTS, IS NOT UNREASONABLY HINDERED.
19	THE SCOPE OF THE STATUTE IS NOT AS BROAD
20	AS OUR EXISTING REGULATIONS. FOR EXAMPLE, OUR
21	REGULATIONS REQUIRE THAT COLLABORATORS SHARE A
22	FRACTION OF THE REVENUES THEY RECEIVE FROM
23	CIRM-FUNDED INVENTIONS. BUT THE STATUTE IS
24	PERMISSIVE AND IT PERMITS SIMPLY THE FLEXIBILITY TO
25	ADOPT REGULATIONS THAT EXCEED THE MINIMUM

9

1	REQUIREMENTS OF THE STATUTE.
2	SO, AGAIN, THE IMPORTANT ASPECT OF THIS
3	PROVISION IS THAT WHILE IT CODIFIES MUCH OF OUR
4	REGULATIONS REGARDING REVENUE SHARING, IT PERMITS
5	THE BOARD TO CONTINUE TO EXERCISE DISCRETION IN THE
6	FUTURE TO MODIFY THOSE FORMULAS IN ORDER TO ENSURE
7	THAT CIRM IS ABLE TO ACHIEVE THE GOALS OF PROP 71.
8	NEXT, THE BILL WOULD ELIMINATE WHAT IS A
9	CURRENT 15-MEMBER CAP ON SCIENTIFIC MEMBERS OF THE
10	GRANTS WORKING GROUP. AS YOU KNOW, CURRENTLY WE
11	HAVE BOTH REGULAR MEMBERS AND ALTERNATE MEMBERS.
12	THIS AMENDMENT WOULD PERMIT US TO ELIMINATE THAT
13	DISTINCTION WHILE MAINTAINING THE 15-SCIENTIST
14	MEMBER LIMIT ON EACH PEER REVIEW PANEL.
15	ONE OF THE MORE SIGNIFICANT PROVISIONS OF
16	THE BILL WOULD REQUIRE CIRM TO ENGAGE AN
17	ADMINISTRATIVE PERFORMANCE AUDIT EVERY THREE YEARS
18	BEGINNING IN FISCAL YEAR 2010-2011. THIS FISCAL
19	AUDIT WOULD COVER CIRM'S OPERATIONS AND POLICIES TO
20	EVALUATE WHETHER THE AGENCY IS APPLYING BEST
21	PRACTICES AND WHETHER OR NOT IT'S COMPLYING WITH ITS
22	OWN POLICIES AND PROCEDURES.
23	THIS REVIEW WOULD NOT REQUIRE A REVIEW OF
24	SCIENTIFIC PERFORMANCE, ALTHOUGH THAT COULD
25	CERTAINLY BE INCLUDED WITHIN THE SCOPE OF ANY AUDIT
	10

THE AGENCY COMMISSIONS.

1

2 THE BILL WOULD ALSO CODIFY ONE OF OUR 3 CURRENT PRACTICES, WHICH IS TO POST VOTE TALLIES 4 ALONG WITH RECUSALS FOR EACH BOARD MEETING. IT 5 WOULD CODIFY SOMETHING THAT'S ALREADY UNDER WAY, 6 WHICH IS TRANSITION PLANNING; THAT IS, PLANNING FOR 7 THE EVENTUAL EXPIRATION OF BOND FUNDING, WHICH THE 8 AGENCY IS ALREADY ENGAGED IN. AND IT WOULD REQUIRE 9 US TO PRODUCE A REPORT REGARDING THE FUTURE PLANS BY JANUARY 31ST, 2012. 10

11 AND FINALLY, THE BILL WOULD REQUIRE THE 12 AGENCY, THE BOARD, TO ENGAGE IN SUCCESSION PLANNING 13 TO ASSESS ITS LEADERSHIP NEEDS IN LIGHT OF THE 14 UPCOMING TRANSITION WITH THE EXPIRATION OF BOARD 15 MEMBER TERMS, INCLUDING THE CHAIR AND VICE CHAIRS. 16 THE EVALUATION SUBCOMMITTEE HAS ALREADY BEGUN TO 17 DISCUSS THESE ISSUES. BOTH THE EVALUATION 18 SUBCOMMITTEE AND THE BOARD WILL HAVE AN OPPORTUNITY 19 TO DISCUSS THESE ISSUES MORE IN THE FUTURE. 20 THERE ARE A COUPLE OF TECHNICAL ISSUES 21 THAT WE RAISED WITH THE AUTHOR, SENATOR ALQUIST, AND

THAT WE RAISED WITH THE AUTHOR, SENATOR ALQUIST, AND
SHE IS SUPPORTIVE OF OUR REQUEST FOR AMENDMENTS TO
CORRECT THOSE ISSUES. HOWEVER, GIVEN THE TIMING,
IT'S LIKELY THAT THOSE AMENDMENTS WILL NOT BE MADE
UNTIL THE BILL REACHES THE ASSEMBLY. BUT SENATOR

11

1	ALQUIST IS SUPPORTIVE.
2	SO WHAT WE WOULD RECOMMEND IS THAT THE
3	BOARD ENDORSE THE BILL, BUT RESERVE THE RIGHT TO
4	REVIEW FOR TECHNICAL PROFICIENCY.
5	VICE CHAIRMAN TORRES: ALL RIGHT. THANK
6	YOU VERY MUCH, JAMES. SHERRY LANSING COULD NOT BE
7	WITH US TODAY, BUT SHE AND I SPOKE LAST EVENING AND
8	SHE SUPPORTS THE RECOMMENDATION ON THIS LEGISLATION.
9	AGAIN, MY THANKS TO MELISSA KING AND NICK
10	WARSHAW FOR HANDLING ALL THE LOGISTICS OF ALL OF
11	THESE DISCUSSIONS AND MEETINGS IN SACRAMENTO. THANK
12	YOU VERY MUCH FOR YOUR HELP.
13	ANY COMMENTS FROM MEMBERS OF THE BOARD?
14	CHAIRMAN KLEIN: ART, THIS IS BOB KLEIN.
15	I WOULD LIKE TO COMMEND YOUR LEADERSHIP AND DUANE
16	ROTH'S TREMENDOUS COMMITMENT TO THIS EFFORT. AND
17	BOTH JAMES HARRISON AND SCOTT TOCHER FOR THEIR DEEP
18	COMMITMENT TO THE PROCESS WHICH WAS EXTREMELY
19	TIME-CONSUMING AND INTENSE.
20	VICE CHAIRMAN TORRES: I GIVE THE
21	CHAIRMANSHIP BACK TO YOU, BOB.
22	CHAIRMAN KLEIN: IN LOOKING AT THIS, THIS
23	IS A PROCESS THAT HAS TAKEN A GREAT DEAL OF TIME AND
24	MERGED HOPEFULLY A VERY POSITIVE RELATIONSHIP WITH
25	MEMBERS OF THE LEGISLATURE. CERTAINLY THE AUTHOR,
	12

-	
1	SENATOR ALQUIST, HAS WORKED WELL WITH US AT THIS
2	POINT. THE SENATE PRO TEM DARRELL STEINBERG, AS
3	MENTIONED, HAS BEEN A VERY IMPORTANT LEADER IN THIS
4	PROCESS ALONG WITH THEIR STAFFS.
5	AND I WOULD LIKE TO GET COMMENTS FROM
6	OTHER MEMBERS AND THEIR LOCATIONS. AND, MELISSA,
7	COULD YOU POLL THE LOCATIONS SO WE CAN SEE WHAT
8	THOSE COMMENTS MIGHT BE?
9	MS. KING: ACTUALLY WHAT I'D LIKE TO DO
10	BEFORE THAT, IF I COULD, CHAIRMAN KLEIN, IS ASK
11	ANYBODY WHO'S JOINED THE MEETING SINCE THE ROLL CALL
12	AND, THEREFORE, HASN'T BEEN CALLED OR RECOGNIZED AS
13	HAVING JOINED THE MEETING, IF YOU COULD LET ME KNOW
14	WHO YOU ARE THAT, WOULD BE GREAT.
15	MS. SAMUELSON: JOAN SAMUELSON.
16	MS. KING: THANK YOU, JOAN. ANYBODY ELSE?
17	DR. BIRGENEAU: BOB BIRGENEAU. I JUST
18	JOINED THE CALL A FEW MINUTES AGO.
19	MS. KING: OKAY. GREAT. THANKS, DR.
20	BIRGENEAU.
21	MR. TORRES: DR. TROUNSON HAS JOINED US
22	SINCE THE ROLL CALL AS WELL.
23	DR. AZZIZ: AND YOU TOOK MY NAME DOWN,
24	MELISSA, RICARDO?
25	MS. KING: YES. THANK YOU VERY MUCH, DR.
	13

1	AZZIZ. ALL RIGHT.
2	WHY DON'T WE JUST ASK WHOEVER HAS A
3	COMMENT TO MAKE A COMMENT.
4	DR. DAFOE: MELISSA, SINCE DR. AZZIZ IS ON
5	THE CALL, I WILL BAIL OUT BECAUSE I'M THE ALTERNATE.
6	MS. KING: THAT IS CORRECT. WE CAN ONLY
7	COUNT ONE OF YOU AS PRESENT; BUT DR. DAFOE, WE
8	APPRECIATE YOU BEING HERE. AND IF YOU WOULD LIKE TO
9	STAY ON THE LINE AND SHOULD YOU HAVE A COMMENT,
10	YOU'RE MORE THAN WELCOME TO MAKE A COMMENT.
11	DR. DAFOE: ALL RIGHT. THANK YOU.
12	MS. SAMUELSON: I'VE GOT A QUESTION FOR
13	JAMES. THIS IS JOAN.
14	MR. HARRISON: SURE.
15	MS. SAMUELSON: COULD YOU JUST REPEAT WHAT
16	THE TERMS OF THE LIFTING OF THE 15-MEMBER CAP ON THE
17	WORKING GROUP WAS ABOUT?
18	MR. HARRISON: YES. SO AS YOU KNOW, JOAN,
19	CURRENTLY WE HAVE 15 WE'RE LIMITED TO 15 REGULAR
20	MEMBERS OF THE GRANTS WORKING GROUP, 15 SCIENTIFIC
21	MEMBERS. BECAUSE OUR NEEDS ARE GREATER THAN 15 WHO
22	CAN SERVE ON ALL THE PEER REVIEW PANELS THAT WE NEED
23	IN ORDER TO PROCESS GRANTS, WE RELY ON ALTERNATES
24	AND SPECIALISTS AS WELL. WHAT THIS BILL WOULD DO
25	WOULD ESSENTIALLY BE TO ALLOW US TO HAVE A LARGER

14

POOL OF SCIENTISTS WHO WE CALL REGULAR MEMBERS,
 ALTHOUGH EACH PEER REVIEW PANEL WOULD CONTINUE TO BE
 COMPRISED OF ONLY 15 SCIENTISTS AND THE PATIENT
 ADVOCATES.

5 CHAIRMAN KLEIN: JOAN, THIS BOB. THIS 6 DOES NOT SUBSTANTIVELY CHANGE OUR PROCESS. WHAT IT 7 MEANS, THOUGH, IS THAT INSTEAD OF THE ADDITIONAL 8 MEMBERS BEING ALTERNATES, THEY WOULD BE CONSIDERED 9 FULL MEMBERS. BUT IT DOESN'T CHANGE THE FACT THAT THERE WILL BE 15 SCIENTISTS SO THAT THE RATIO OF 10 SCIENTISTS TO PATIENT ADVOCATES ON ANY PEER REVIEW 11 12 DOES NOT CHANGE. THE STRUCTURE REMAINS INTACT AS 13 ENVISIONED BY THE INITIATIVE.

MS. SAMUELSON: IT CHANGES IT FOR OTHER
PURPOSES OTHER THAN PEER REVIEW AND PROGRAMMATIC
REVIEW. AND DOES THIS MAKE THE CHANGE, OR DOES IT
PERMIT THE WORKING GROUPS AND THE BOARD TO DO SO?

18 MR. HARRISON: NO. CURRENTLY PROP 71 19 SPECIFIES THAT THERE ARE ONLY 15 SCIENTIFIC MEMBERS 20 OF THE GRANTS WORKING GROUP. THIS WOULD REMOVE THAT 21 LIMIT, SO THERE WOULD BE A MINIMUM OF 15 SCIENTIFIC 22 MEMBERS OF THE GRANTS WORKING GROUP. THE AGENCY AND 23 THE BOARD CAN DESIGNATE ADDITIONAL ALTERNATES AS 24 REGULAR MEMBERS UNDER THIS PROVISION, BUT THE 25 LEGISLATION WOULD LIFT THAT CAP, AGAIN, WHILE

15

1	MAINTAINING THE CURRENT COMPOSITION OF EACH PEER
2	REVIEW PANEL OF 15 SCIENTIFIC MEMBERS AND PATIENT
3	ADVOCATES.
4	MS. SAMUELSON: OKAY.
5	DR. PRIETO: I HAD A QUESTION FOR JAMES
6	AND MAYBE JUST A CLARIFICATION. WHAT IS THE IMPACT
7	OF THE CHANGE IN THE STAFFING CAP FOR THE AGENCY IF
8	WE'RE STILL UNDER THE 6-PERCENT CEILING?
9	PRACTICALLY SPEAKING, HOW MUCH MORE STAFF WOULD THAT
10	ALLOW US TO HIRE?
11	MR. HARRISON: WELL, I WILL TURN TO JOHN
12	ROBSON TO ANSWER THAT QUESTION. I WILL POINT OUT
13	THAT WE'VE BEEN OPERATING AT SIGNIFICANTLY UNDER THE
14	6-PERCENT CAP SINCE THE AGENCY'S INCEPTION.
15	DR. ROBSON: SO WE'VE DONE SOME RESEARCH
16	INTO THIS. WE'VE DONE SOME MODELING. AND WE THINK
17	we would go to somewhere between 55 and 60 we would
18	NEED TO DO. IF WE GET ABOVE 60, WE HAVE PROBLEMS
19	FINDING SPACE FOR EVERYONE TO SIT IN OUR OFFICE, AND
20	IT WOULD THEN SHORTEN THE LIFE SPAN OF THE 6 PERCENT
21	WE HAVE IN OVERHEAD IN THAT WE WOULD RUN INTO A
22	MISMATCH IF WE WOULD RUN OUT OF OVERHEAD BEFORE WE
23	RUN OUT OF MONEY TO ALLOCATE TOWARD GRANTS.
24	CHAIRMAN KLEIN: DR. PRIETO, TO THE EXTENT
25	THAT THERE ARE CONTRIBUTIONS WHICH WE'VE RECEIVED IN
	16

1	THE PAST, THIS IS, OF COURSE, BOB KLEIN SPEAKING, WE
2	COULD USE THOSE TO COVER PART OF THE COST OF THE
3	ADDITIONAL STAFF. SO WE'RE REMAINING AS WE ALWAYS
4	HAVE AS SET UP BY THE INITIATIVE CONSTRAINED BY 6
5	PERCENT IN STATE FUNDS, BUT CONTRIBUTIONS TO THE
6	AGENCY CAN BE USED TO SUPPORT THIS ADDITIONAL STAFF.
7	DR. PRIETO: AS WE DID IN THE EARLY DAYS.
8	CHAIRMAN KLEIN: RIGHT.
9	DR. PRIETO: A SEPARATE QUESTION FOR
10	JAMES, I THINK, ABOUT THE IP WORDING. DOES THE
11	WORD THE WAY YOU READ IT TO US, DOES THE WORDING
12	ACTUALLY INCLUDE DRUG, OR IS IT MORE EXPANSIVE, I
13	GUESS? OBVIOUSLY WE'RE NOT NECESSARILY THINKING
14	ABOUT DRUGS IN CELLULAR THERAPIES AND OTHER
15	PRODUCTS.
16	MR. HARRISON: THE WORDING DOES INCLUDE
17	THE TERM "DRUG" AS DO OUR REGULATIONS. HOWEVER,
18	WHAT'S REALLY CRITICAL IS THAT THE STATUTE
19	AUTHORIZES THE BOARD TO ADOPT REGULATIONS TO
20	IMPLEMENT THIS PROVISION INCLUDING SPECIFICALLY
21	DEFINING THE TERMS THAT ARE USED. FOR EXAMPLE, ONE
22	OF THE TERMS THAT'S USED IS TO MAKE THESE DRUGS
23	AVAILABLE TO CALIFORNIANS WITH NO MEANS. BOTH THOSE
24	TERMS, A DRUG, WHICH IS CURRENTLY DEFINED IN OUR
25	REGULATIONS AS CALIFORNIANS WITH NO MEANS, WOULD BE

17

1	DEFINED THROUGH REGULATORY EFFORTS. AND BY THE WAY,
2	OUR CURRENT REGULATORY DEFINITION OF DRUG INCLUDES
3	THERAPIES.
4	DR. PRIETO: OKAY.
5	MS. SAMUELSON: JAMES, AS FOLLOW-UP ON
6	THAT FROM JOAN. DOES THE STATUTE CHANGE THE LAW ON
7	THE PRICING AUTOMATICALLY, OR DOES IT PERMIT US
8	TO DO SO?
9	MR. HARRISON: THE STATUTE DOES NOT
10	ADDRESS THE CALRX ISSUE AT ALL. OUR REGULATIONS
11	CONTINUE TO ADDRESS IT, AND THE BOARD WOULD RETAIN
12	ITS FULL AUTHORITY TO MODIFY THAT IN THE FUTURE IF
13	IT CHOSE TO DO SO. IT'S NOT ADDRESSED BY THE BILL.
14	MS. SAMUELSON: ALL RIGHT.
15	MS. GIBBONS: THIS IS LEEZA WITH A
16	QUESTION ABOUT THE CHANGES IN THIS REGARDING OUR
17	LEADERSHIP, THE CHAIRPERSON AND THE VICE
18	CHAIRPERSON. I'M LOOKING AT THE TERMS. I GOT THAT.
19	DOES THIS ACCOMMODATE OUR CURRENT SITUATION WITH TWO
20	VICE CHAIRS IF WE GO FORWARD?
21	MR. HARRISON: THE BILL IS SILENT ON THAT
22	ISSUE ENTIRELY. THE TWO VICE CHAIR MODEL THAT WE'VE
23	DEVELOPED WAS DEVELOPED THROUGH OUR BYLAWS WHICH THE
24	BOARD WILL CONTINUE TO HAVE FULL AUTHORITY OVER. SO
25	THIS BILL DOESN'T IN ANY WAY IMPEDE THE BOARD IN
	18

18

1 THAT AREA. 2 MS. GIBBONS: THANK YOU. 3 DR. LOVE: I DIDN'T HAVE A QUESTION, BUT I 4 DID HAVE A COMMENT THAT I DIDN'T PARTICIPATE IN ANY 5 OF THIS PROCESS, SO I JUST READ ALL THESE DOCUMENTS KIND OF IN RETROSPECT. AND I'M JUST AMAZED AT HOW 6 7 SUCCESSFUL YOU ALL HAVE BEEN AT CHANGING SOME VERY CONCERNING THINGS INTO THINGS THAT AT THE END OF THE 8 9 DAY REALLY ARE POSITIVE FOR US OR THINGS THAT ARE 10 FAIRLY NEUTRAL FOR US. SO I WOULD JUST CONGRATULATE 11 THE WHOLE TEAM FOR DEALING WITH THIS SO ADEPTLY. 12 CHAIRMAN KLEIN: SO IF THERE ARE NO OTHER 13 COMMENTS, A RESOLUTION WOULD BE A -- A MOTION WOULD 14 BE IN ORDER. 15 MR. TORRES: MR. CHAIRMAN, I MOVE THAT WE 16 SUPPORT SB 1064 IN ITS CURRENT FORM, BUT RESERVE THE 17 RIGHT TO REVIEW FOR TECHNICAL PROFICIENCY. 18 CHAIRMAN KLEIN: I WOULD TAKE IT, SENATOR 19 TORRES, THAT YOU'RE ALSO RESERVING THE RIGHT TO 20 CHANGE THAT POSITION IF, IN FACT, THE BILL WERE TO BE CHANGED UNEXPECTEDLY AS IT MOVES THROUGH THE 21 22 LEGISLATURE. 23 MR. TORRES: I DON'T THINK WE NEED TO SAY 24 THAT, BUT THAT'S INHERENT IN ANY RESOLUTION TO 25 SUPPORT.

1	CHAIRMAN KLEIN: GREAT.
2	MS. GIBBONS: I SECOND ART'S MOTION.
3	MS. SAMUELSON: QUESTION FOR COUNSEL.
4	THIS IS JOAN. FOR THOSE OF US WHOSE COMPENSATION IS
5	AFFECTED BY THIS, WE PROBABLY SHOULD HAVE SOME
6	RECUSALS, RIGHT?
7	MR. HARRISON: JOAN, THIS BILL DOESN'T
8	DIRECTLY AFFECT YOUR COMPENSATION. THE BOARD WOULD
9	HAVE TO ACT IN ORDER TO DO THAT. ALL THIS DOES IS
10	TO GIVE THE BOARD AUTHORITY TO DO SO.
11	MS. SAMUELSON: OKAY.
12	CHAIRMAN KLEIN: BUT GOOD QUESTION, JOAN.
13	WE ALWAYS HAVE TO BE VIGILANT ON THOSE MATTERS.
14	MS. SAMUELSON: YEAH. I ALMOST HAD MY
15	FIRST CONFLICT OF INTEREST. ALMOST.
16	CHAIRMAN KLEIN: ALL RIGHT. SO, MELISSA
17	KING, COULD YOU WELL, FIRST OF ALL, HAVE WE HAD
18	ANY COMMENT FROM THE PUBLIC AT ANY OF THE SITES?
19	ARE THERE ANY MEMBERS OF THE PUBLIC WHO WOULD LIKE
20	TO ADDRESS THIS?
21	MS. KING: WE HAVE ONE MEMBER OF THE
22	PUBLIC HERE IN SAN FRANCISCO, DON REED, WHO WOULD
23	LIKE TO MAKE A COMMENT.
24	MR. REED: THIS IS GREAT. IT ANSWERS SOME
25	NEEDS OF CIRM STAFFING. AS ANY COMPROMISE, THERE'S
	20
	20

1	THINGS I WOULD REMOVE. I REALLY DON'T SEE A NEED
2	FOR YET ANOTHER LAYER OF AUDITING, BUT I REGARD THAT
3	MORE AS A MINOR ANNOYANCE THAT WILL TAKE UP STAFF
4	TIME AND JUST ONE MORE WAY OF SHOWING THAT CIRM IS
5	DOING A FANTASTIC JOB. BUT BASICALLY THIS IS A GOOD
6	THING. I THINK THE PATIENT ADVOCACY COMMUNITY CAN
7	SUPPORT IT.
8	CHAIRMAN KLEIN: ALL RIGHT. ANY OTHER
9	COMMENTS FROM AROUND THE STATE FROM THE PUBLIC? ARE
10	THERE ANY LEGISLATIVE MEMBERS THAT ARE AT ANY OF THE
11	LOCATIONS?
12	MR. TORRES: JUST EX.
13	CHAIRMAN KLEIN: OKAY. ALL RIGHT. AND
14	AGAIN, I THINK WE SHOULD THANK SENATOR ALQUIST AND
15	HER STAFF AND SENATOR DARRELL STEINBERG AND HIS
16	STAFF FOR THEIR REALLY ENGAGED AND COMMITTED
17	INVOLVEMENT, AND WE SHOULD THANK ART TORRES FOR
18	LEADING THIS AND DUANE FOR HIS TREMENDOUS
19	INVOLVEMENT.
20	AND I WOULD SAY THAT IN THIS PROCESS I
21	PERSONALLY VISITED SOME, IN ADDITION TO SENATOR
22	ALQUIST, SOME OF THE REPUBLICAN REPRESENTATIVES.
23	AND DUANE HAS AS WELL. AND I THINK WE HAVE SOME
24	BIPARTISAN LEVEL OF SUPPORT FOR WHAT WE'RE DOING
25	HERE.

21

-	
1	MR. TORRES: PLUS SENATOR KEHOE AS CHAIR
2	OF THE APPROPRIATIONS COMMITTEE AND SENATOR FLORES
3	AND THEIR STAFFS.
4	CHAIRMAN KLEIN: ABSOLUTELY. ABSOLUTELY.
5	SENATOR FLORES WAS CERTAINLY VERY IMPORTANT AT THE
6	BEGINNING OF THIS PROCESS TO GET THE BASIC CONCEPT
7	OF THE AGREEMENTS AND THE FORMAL AGREEMENTS THAT
8	WOULD MOVE FORWARD. SO WE THANK HIM ESPECIALLY
9	ALONG WITH SENATOR KEHOE AND ALL OF DUANE'S WORK
10	WITH HER.
11	MR. TORRES: YES.
12	CHAIRMAN KLEIN: ALL RIGHT. MELISSA,
13	COULD YOU CALL THE ROLL, PLEASE.
14	MS. KING: I WILL DO THAT AND IT MAY BE
15	THE CASE THAT WE'RE WAITING FOR ONE MORE MEMBER TO
16	JOIN. IT'S POSSIBLE THAT INDIVIDUAL HAS JOINED AND
17	WE DIDN'T NOTICE. SO I'LL GO THROUGH THE ROLL AND
18	WE'LL SEE.
19	RICARDO AZZIZ.
20	DR. AZZIZ: IN FAVOR.
21	MR. TORRES: AND SECONDED BY LEEZA
22	GIBBONS.
23	MS. KING: SECONDED BY LEEZA. THANK YOU.
24	THANK YOU. FOR THE RECORD.
25	ROBERT BIRGENEAU.
	22

	D	
1	DR.	BIRGENEAU: YES.
2	MS.	KING: FLOYD BLOOM.
3	DR.	BLOOM: YES.
4	MS.	KING: WILLIAM BRODY.
5	DR.	BRODY: AYE.
6	MS.	KING: DR. LEVIN.
7	DR.	LEVIN: AYE.
8	MS.	KING: LEEZA GIBBONS.
9	MS.	GIBBONS: YES.
10	MS.	KING: GERALD LEVEY.
11	DR.	LEVEY: YES.
12	MS.	KING: TED LOVE.
13	DR.	LOVE: YES.
14	MS.	KING: ED PENHOET.
15	DR.	PENHOET: YES.
16	MS.	KING: FRANCISCO PRIETO.
17	DR.	PRIETO: AYE.
18	MS.	KING: ROBERT QUINT. JEANNIE FONTANA.
19	DR.	FONTANA: YES.
20	MS.	KING: DUANE ROTH.
21	MR.	ROTH: YES.
22	MS.	KING: DAVID SERRANO-SEWELL. JOAN
23	SAMUELSON.	
24	MS.	SAMUELSON: YES.
25	MR.	SERRANO-SEWELL: DAVID SERRANO-SEWELL
		23

BARRISTERS' REPORTING SERVICE 1 IS A YES. 2 MS. KING: THANK YOU. JEFF SHEEHY. 3 MR. SHEEHY: YES. 4 MS. KING: JON SHESTACK. 5 MR. SHESTACK: YES. 6 MS. KING: OSWALD STEWARD. AND ART 7 TORRES. 8 MR. TORRES: AYE. 9 MS. KING: ROBERT KLEIN. 10 CHAIRMAN KLEIN: YES. 11 MS. KING: WE ARE STILL, HOWEVER, ONE 12 SHORT. 13 CHAIRMAN KLEIN: SO WHAT I'D LIKE TO DO IS 14 LEAVE THIS ROLL CALL OPEN WHILE MAYBE SOME OF THE 15 SUPPORTING STAFF OF MELISSA COULD MAKE A CALL. AND 16 THEN I'D LIKE TO MOVE ON TO THE SECOND ITEM ON THE 17 AGENDA IF WE COULD. MS. KING: WHO JUST JOINED? 18 19 DR. QUINT: DR. QUINT. MS. KING: GREAT. THANK YOU SO MUCH, 20 DR. QUINT. AND THANKS TO AMY FOR MAKING THAT 21 22 POSSIBLE. 23 SO I WOULD REQUEST THAT JAMES HARRISON, 24 LEGAL COUNSEL, WOULD JUST VERY BRIEFLY GO THROUGH 25 THE MOTION THAT'S ON THE TABLE FOR DR. QUINT, AND 24

1	THEN, DR. QUINT, WE CAN GET YOUR VOTE AND MOVE
2	QUICKLY TO THE PROPOSED ADDITIONAL AGENDA ITEM SO
3	THAT EVERYBODY CAN GO BACK TO OTHER BUSINESS THIS
4	MORNING.
5	CHAIRMAN KLEIN: AND, DR. QUINT, THE
6	MOTION THAT IS GOING TO BE REVIEWED HERE FOR YOU BY
7	JAMES HARRISON IS SUPPORTED BY THE EXECUTIVE
8	COMMITTEE. AND THERE IS A ROLL CALL IN PROCESS
9	WHERE ALL OF THE VOTES THUS FAR HAVE BEEN POSITIVE.
10	MS. KING: WHO JUST JOINED?
11	CHAIRMAN KLEIN: LET ME SAY TO THE OTHER
12	MEMBERS ON THE CALL, WE DO HAVE ANOTHER ITEM ON THIS
13	AGENDA. SO PLEASE STAY WITH US. WE'LL NEED A
14	TWO-THIRDS VOTE TO ADD IT TO THE AGENDA FORMALLY.
15	MR. HARRISON: GOOD MORNING, DR. QUINT.
16	THE MOTION THAT'S ON THE TABLE IS TO SUPPORT SENATE
17	BILL NO. 1064, BUT TO RESERVE THE RIGHT TO REVIEW
18	THE BILL FOR TECHNICAL PROFICIENCY. THE BILL, IN
19	SUMMARY, WOULD ELIMINATE THE 50-EMPLOYEE CAP WHILE
20	REQUIRING CIRM TO REMAIN WITHIN THE 6-PERCENT CAP ON
21	ADMINISTRATIVE EXPENDITURES. IT WOULD PERMIT THE
22	BOARD TO PROVIDE REASONABLE COMPENSATION TO PATIENT
23	ADVOCATES FOR THEIR SERVICE ON THE WORKING GROUPS,
24	AND IT WOULD CODIFY CERTAIN PRACTICES AND
25	REGULATIONS THAT ARE ALREADY IN EFFECT WHILE

25

1	MAINTAINING THE AGENCY'S FLEXIBILITY TO MAKE CHANGES
2	IN THE FUTURE.
3	AND THE QUESTION ON THE TABLE TO YOU IS
4	WHETHER YOU SUPPORT OR OPPOSE THE MOTION.
5	DR. QUINT: YES. I HAVE IT RIGHT IN FRONT
6	OF ME HERE. YES, I DO SUPPORT IT.
7	MR. HARRISON: THANK YOU.
8	MS. KING: THANK YOU, DR. QUINT. AND WITH
9	THAT, CHAIRMAN KLEIN, IF YOU COULD MOVE TO THE
10	PROPOSED ADDITIONAL AGENDA ITEM, THAT WOULD BE
11	GREAT. THANK YOU.
12	FOR THE RECORD THAT MOTION CARRIES.
13	CHAIRMAN KLEIN: SO, MR. HARRISON, COULD
14	YOU INTRODUCE THE ADDITIONAL PROPOSED AGENDA ITEM.
15	AND, AGAIN, IT WILL TAKE A TWO-THIRDS VOTE TO PUT
16	THIS FORMALLY ON THE AGENDA. SO THEN THE SECOND
17	VOTE WOULD BE ON ITS APPROVAL OR DENIAL. MR.
18	HARRISON.
19	MR. HARRISON: AS MOST OF YOU KNOW, THE
20	INTERNATIONAL SOCIETY FOR STEM CELL RESEARCH WILL BE
21	HOLDING ITS ANNUAL MEETING HERE IN SAN FRANCISCO IN
22	JUNE. THE PROPOSAL THAT IS ON THE TABLE IS AN ITEM
23	THAT WOULD PERMIT THE BOARD TO AUTHORIZE A
24	CONFERENCE GRANT TO THE INTERNATIONAL SOCIETY FOR
25	STEM CELL RESEARCH FOR THE PURPOSES OF DEFRAYING THE
	26

1	REGISTRATION FEES AND INCIDENTAL COSTS FOR CIRM
2	TRAINING GRANT PARTICIPANTS, BRIDGES TO STEM CELL
3	RESEARCH MASTER'S DEGREE CANDIDATES, AND POST DOCS
4	AND GRADUATE STUDENTS ON CIRM-FUNDED RESEARCH GRANTS
5	SO THAT THEY COULD PARTICIPATE IN THIS CONFERENCE,
6	WHICH UNFORTUNATELY DOESN'T TAKE PLACE IN CALIFORNIA
7	EVERY YEAR.
8	IN ORDER TO CONSIDER THIS ITEM, THE BOARD
9	HAS TO MAKE A DETERMINATION THAT THE NEED FOR ACTION
10	ON THIS ITEM CAME TO THE BOARD'S ATTENTION AFTER THE
11	AGENDA WAS POSTED AND THAT IT'S NECESSARY TO TAKE
12	ACTION ON THIS ITEM NOW BEFORE THE NEXT REGULARLY
13	SCHEDULED BOARD MEETING.
14	CHAIRMAN KLEIN: SO, FIRST OF ALL, SO THAT
15	WE KNOW WHERE WE ARE, COULD WE DO A VERY QUICK ROLL
16	CALL TO SEE IF WE LOST SOMEONE WHEN WE HEARD THE
17	SOUND OF POTENTIALLY SOMEONE SIGNING OFF, MELISSA.
18	SO AS A LEAD-TIME ITEM, IF WE HAVE LOST SOMEONE, WE
19	COULD GET SOMEONE TO CALL THEM.
20	MS. KING: RICARDO AZZIZ. ARE YOU STILL
21	PRESENT, DR. AZZIZ?
22	DR. AZZIZ: I AM.
23	MS. KING: ROBERT BIRGENEAU.
24	DR. BIRGENEAU: YES.
25	MS. KING: FLOYD BLOOM.
	27

27

1	DR. BLOOM: YES.
2	MS. KING: WILLIAM BRODY.
3	DR. BRODY: HERE.
4	MS. KING: JACOB LEVIN.
5	DR. LEVIN: HERE.
6	MS. KING: LEEZA GIBBONS.
7	MS. GIBBONS: STILL HERE.
8	MS. KING: BOB KLEIN.
9	CHAIRMAN KLEIN: YES.
10	MS. KING: GERALD LEVEY. DR. LEVEY, ARE
11	YOU STILL WITH US? I'LL COME BACK TO DR. LEVEY. I
12	KNOW HE HAD ONE THING HE NEEDED TO DO CLOSE TO THE
13	END OF THIS CALL. HE MAY HAVE HAD TO STEP OUT FOR A
14	MOMENT.
15	TED LOVE.
16	DR. LOVE: HERE. BUT I HAVE A HARD STOP
17	AT NINE.
18	MS. KING: ED PENHOET.
19	DR. PENHOET: HERE.
20	MS. KING: PHIL PIZZO. FRANCISCO PRIETO.
21	DR. PRIETO: HERE.
22	MS. KING: ROBERT QUINT.
23	DR. QUINT: PRESENT.
24	MS. KING: JEANNIE FONTANA.
25	DR. FONTANA: PRESENT.
	28

1	MS. KING: DUANE ROTH.
2	MR. ROTH: HERE.
3	MS. KING: JOAN SAMUELSON.
4	MS. SAMUELSON: PRESENT.
5	MS. KING: DAVID SERRANO-SEWELL. JEFF
6	SHEEHY.
7	MR. SHEEHY: HERE.
8	MS. KING: JON SHESTACK.
9	MR. SHESTACK: HERE.
10	MR. SERRANO-SEWELL: DAVID IS HERE.
11	MS. KING: THANKS, DAVID. AND ART TORRES
12	IS PRESENT.
13	MR. TORRES: HERE.
14	MS. KING: SO WE MAY HAVE MOMENTARILY LOST
15	DR. LEVEY, BUT UNFORTUNATELY WE DON'T HAVE
16	DR. LEVEY: I'M HERE.
17	MS. KING: THANKS, DR. LEVEY. I SUGGEST
18	WE MOVE FORWARD AS QUICKLY AS WE CAN. SEVERAL
19	PEOPLE HAVE A HARD STOP AT NINE, AND WE DON'T
20	ACTUALLY HAVE THAT MANY OTHER OPTIONS.
21	CHAIRMAN KLEIN: GREAT. I THINK THIS IS
22	GOING TO BE A FAIRLY SUCCINCT DISCUSSION. SO WE
23	SHOULD BE ABLE TO OPERATE WITHIN THOSE LIMITS.
24	MR. ROTH: BOB, I'LL MAKE THE MOTION THAT
25	WE NEED TO CONSIDER THIS AT THE PRESENT TIME.
	29

1	MR. SHESTACK: SECOND.
2	CHAIRMAN KLEIN: OKAY. THERE'S A MOTION
3	AND A SECOND.
4	MS. KING: SECOND WAS FROM JON SHESTACK.
5	CHAIRMAN KLEIN: IS THERE PUBLIC COMMENT
6	ON THE QUESTION OF WHETHER TO CONSIDER IT? ANY
7	BOARD COMMENT ON THE QUESTION OF WHETHER TO CONSIDER
8	IT? PLEASE CALL THE ROLL CALL ON WHETHER WE WILL
9	CONSIDER THIS.
10	MS. KING: RICARDO AZZIZ.
11	DR. AZZIZ: YES.
12	MS. KING: ROBERT BIRGENEAU.
13	DR. BIRGENEAU: YES.
14	MS. KING: FLOYD BLOOM.
15	DR. BLOOM: YES.
16	MS. KING: WILLIAM BRODY.
17	DR. BRODY: YES.
18	MS. KING: JACOB LEVIN.
19	DR. LEVIN: YES.
20	MS. KING: LEEZA GIBBONS.
21	MS. GIBBONS: YES.
22	MS. KING: BOB KLEIN.
23	CHAIRMAN KLEIN: YES.
24	MS. KING: GERALD LEVEY.
25	DR. LEVEY: YES.
	30

	DARRISTERS REFORTING SERVICE
1	MS. KING: TED LOVE.
2	DR. LOVE: YES.
3	MS. KING: ED PENHOET.
4	DR. PENHOET: YES.
5	MS. KING: FRANCISCO PRIETO.
6	DR. PRIETO: YES.
7	MS. KING: ROBERT QUINT.
8	DR. QUINT: YES.
9	MS. KING: JEANNIE FONTANA.
10	DR. FONTANA: YES.
11	MS. KING: DUANE ROTH.
12	MR. ROTH: YES.
13	MS. KING: JOAN SAMUELSON.
14	MS. SAMUELSON: YES.
15	MS. KING: DAVID SERRANO-SEWELL.
16	MR. SERRANO-SEWELL: YES.
17	MS. KING: JEFF SHEEHY.
18	MR. SHEEHY: YES.
19	MS. KING: JON SHESTACK.
20	MR. SHESTACK: YES.
21	MS. KING: AND ART TORRES.
22	MR. TORRES: AYE.
23	MS. KING: THAT MOTION CARRIES.
24	CHAIRMAN KLEIN: ALL RIGHT. SO THIS
25	PARTICULAR ITEM AROSE. THERE WAS SOME DISCUSSION
	31
	JT

1	WITH BOARD MEMBERS AND THERE WAS DISCUSSION WITH
2	MEMBERS OF THE SCIENTIFIC COMMUNITY WHO POINTED OUT
3	THAT, IN FACT, THERE WERE NEW ENTRANTS INTO THE STEM
4	CELL FIELD, EXTREMELY TALENTED YOUNG CIRM SCHOLARS.
5	THEY WERE MASTER'S CANDIDATES IN THE BRIDGE PROGRAM
6	WHO THEY WERE TRYING TO MOTIVATE AT THEIR
7	INSTITUTIONS TO GO ON FOR POSTDOCTORAL WORK OR TO
8	STAY IN THE FIELD IN HIGHLY TECHNICAL POSITIONS.
9	AND THERE ARE POST DOCS AND GRAD STUDENTS WHO ARE AT
10	THE VERY JUNIOR SCALE OF THE SCIENTIFIC GRANTS WE'VE
11	APPROVED WHERE THERE IS NOT ANY ALLOCATION REMAINING
12	OR THERE WAS NEVER ANY ALLOCATION FOR TRAINING GRANT
13	FUNDS EXCUSE ME FOR TRAVEL AND CONFERENCE
14	FUNDS.
15	THERE ARE FUNDS IN THE CIRM TRAINING
16	GRANTS FOR TRAVEL AT THE END OF THE YEAR, AT THE END
17	OF THEIR TWO-YEAR PERIOD. THEY MAY HAVE EXHAUSTED
18	THOSE BY THE TIME THEY COME UP FOR THIS
19	INTERNATIONAL CONFERENCE. AS MR. HARRISON
20	INDICATES, IT MAY BE FIVE YEARS OR MORE BEFORE
21	THERE'S ANOTHER CONFERENCE IN CALIFORNIA WHERE THESE
22	JUNIOR MEMBERS WOULD BE ABLE TO ATTEND AND GET THE
23	BENEFIT OF THE LEARNING EXPERIENCE EXPOSED TO SOME
24	OF THE BEST MINDS IN THE WORLD.
25	JAMES, WOULD YOU LIKE TO GO THROUGH THE
	32

1	DETAILS IN THIS PROPOSAL, PLEASE.
2	MR. HARRISON: SURE. THE PROPOSAL IS TO
3	ALLOCATE UP TO \$226,500 TO ISSCR IN THE FORM OF A
4	CONFERENCE GRANT TO UNDERWRITE THE PARTICIPATION OF
5	UP TO 300 YOUNG RESEARCHERS AND STUDENTS FROM ACROSS
6	THE STATE. THE FUNDS WOULD BE ALLOCATED TO THE
7	ISSCR WHICH WOULD ADMINISTER THE PROGRAM AND WHICH
8	WOULD RETURN ANY UNUSED FUNDS TO THE AGENCY. THESE
9	FUNDS WOULD BE IN ADDITION TO THE FUNDS THE BOARD
10	HAS PREVIOUSLY ALLOCATED FOR THE CIRM CONFERENCE
11	GRANT PROGRAM.
12	IN TERMS OF ELIGIBILITY, THE PROGRAM WOULD
13	BE OPEN TO INDIVIDUALS WHO HAVE NOT YET REGISTERED
14	FOR ISSCR AND WHO FALL INTO ONE OF THREE CATEGORIES.
15	FIRST, CIRM SCHOLARS; THAT IS, THE INDIVIDUALS ARE
16	PARTICIPANT STUDENTS IN ONE OF CIRM'S TRAINING GRANT
17	PROGRAMS. TWO, BRIDGES TO STEM CELL RESEARCH
18	PARTICIPANTS, WHICH WOULD BE LIMITED TO MASTER'S
19	DEGREE CANDIDATES IN ONE OF CIRM'S BRIDGES PROGRAMS.
20	AND THIRD, CIRM RESEARCH GRANT PARTICIPANTS, WHICH
21	WOULD BE LIMITED TO POST DOCS AND GRADUATE STUDENTS
22	WHO ARE IDENTIFIED AS KEY PERSONNEL ON A CIRM-FUNDED
23	RESEARCH GRANT AT A NONPROFIT INSTITUTION.
24	THE SUBMISSION PROCESS WHICH WOULD BE
25	HANDLED BY ISSCR WHICH WOULD REQUIRE ELIGIBLE
	33

33

1	INDIVIDUALS TO SUBMIT A ONE-PAGE REQUEST EITHER
2	SIGNED BY THEIR PROGRAM DIRECTOR OR CIRM SCHOLARS
3	AND BRIDGES STUDENTS OR THE PRINCIPAL INVESTIGATOR
4	FOR KEY PERSONNEL ON A CIRM-FUNDED (INTERRUPTION).
5	THERE WOULD BE AN INSTITUTIONAL LIMIT. NO MORE THAN
6	15 AWARDS WOULD BE MADE TO INDIVIDUALS ASSOCIATED
7	WITH A PARTICULAR INSTITUTION.
8	IN TERMS OF GEOGRAPHIC DISTRIBUTION, THE
9	FUNDS WOULD BE ALLOCATED TO NO MORE THAN 120
10	INDIVIDUALS IN NORTHERN CALIFORNIA DEFINED AS UC
11	SANTA CRUZ AND NORTH, AND NO MORE THAN 180 STUDENTS
12	FROM SOUTHERN CALIFORNIA DEFINED AS SOUTH OF UC
13	SANTA CRUZ, WHICH GENERALLY REFLECTS THE
14	DISTRIBUTION OF GRANTS.
15	THE FUNDING WOULD BE FOR STUDENTS FROM
16	NORTHERN CALIFORNIA 350 TO PAY THE REGISTRATION FEE
17	AND \$150 FOR TRAVEL AND INCIDENTALS FOR A TOTAL OF
18	\$500. AND FOR PARTICIPANTS OF SOUTHERN CALIFORNIA,
19	THEY WOULD BE ELIGIBLE TO RECEIVE \$350 FOR THE
20	REGISTRATION FEE AND \$575 FOR TRAVEL AND INCIDENTALS
21	FOR A TOTAL OF \$925.
22	CHAIRMAN KLEIN: SO THE REGULAR
23	REGISTRATION TO THIS CONFERENCE IS CLOSED SO THAT
24	ANYONE WHO HAD IDENTIFIED FUNDS BEFORE THIS BECAME
25	AVAILABLE HAS USED THOSE FUNDS. IT'S A
	34

34

-	
1	SELF-SELECTION PROCESS WHERE THOSE WHO DID NOT HAVE
2	AVAILABLE FUNDS ARE NOW ELIGIBLE. NO ONE WAS AWARE
3	THAT THIS PROGRAM MIGHT EXIST, AND IT WILL NOT
4	UNLESS THE BOARD APPROVES IT TODAY. SO THEY HAD NO
5	WAY OF ANTICIPATING OR GAMING THE SYSTEM. WE EXPECT
6	THAT THERE ARE, HOWEVER, MANY INDIVIDUALS WHO WOULD
7	LIKE TO GO AND WOULD BENEFIT GREATLY IF THIS
8	ASSISTANCE WERE MADE AVAILABLE.
9	FOR THE PURPOSES OF DISCUSSION, IS THERE
10	ANYONE WHO WOULD LIKE TO MAKE A MOTION IN SUPPORT OF
11	THIS PROPOSAL?
12	DR. PRIETO: I'LL MAKE A MOTION. I'LL
13	MOVE THAT WE SUPPORT THIS PROPOSAL.
14	DR. LOVE: SECOND.
15	CHAIRMAN KLEIN: AND THERE'S A QUESTION
16	FROM A MEMBER.
17	DR. LEVIN: THIS IS JACOB LEVIN FROM
18	IRVINE. BOB, I THINK THIS IS A GREAT IDEA AND JUST
19	THE KIND OF PROGRAM THAT CIRM SHOULD SUPPORT TO
20	EXTEND OUR TRAINING AND TO BRING NEW PEOPLE INTO THE
21	FIELD.
22	I HAVE A QUESTION ABOUT THE RESTRICTION TO
23	PEOPLE WHO HAVEN'T YET REGISTERED. IT ACTUALLY
24	DOESN'T SEEM TO ME QUITE FAIR TO BASICALLY REWARD
25	THE PEOPLE WHO HAVEN'T MADE THE FINANCIAL COMMITMENT
	25
	35

1	WHILE THERE MAY BE STUDENTS WHO HAVE REGISTERED, BUT
2	ARE PUTTING THEMSELVES OR THEIR PI'S UNDER SOME SORT
3	OF SIGNIFICANT FINANCIAL STRESS, BUT WHO ARE FOLKS
4	SO COMMITTED THAT THEY DECIDED IT WOULD BE WORTH IT
5	TO GO ANYWAY. IT SEEMS LIKE THERE'S A SIGNIFICANT
6	AMOUNT OF FUNDS AVAILABLE, AND IT MIGHT BE
7	WORTHWHILE TO OPEN IT UP TO ALL POTENTIAL
8	APPLICANTS, INCLUDING THOSE THAT HAVE ALREADY
9	REGISTERED, GIVING THEM THE OPPORTUNITY TO BE
10	REIMBURSED FOR THE COST THAT THEY HAVE ALREADY PUT
11	OUT OR AT LEAST COMMITTED TO PUTTING OUT.
12	CHAIRMAN KLEIN: WITH THE LEVEL OF TRAVEL
13	AND REIMBURSEMENTS, PARTICULARLY FOR PEOPLE FROM
14	SOUTHERN CALIFORNIA, EVEN INDIVIDUALS ATTENDING
15	UNDER THIS PROGRAM WILL HAVE TO POTENTIALLY
16	CONTRIBUTE SOME OF THEIR OWN FUNDS OR FIND SOME
17	SUPPLEMENTAL FUNDS UNLESS THEY'RE GOING TO STAY WITH
18	FRIENDS IN THE BAY AREA, WHICH THEY MAY WELL DO.
19	SO IT IS IMPORTANT, HOWEVER, TO NOTE THAT
20	THE REGISTRATION WITH THE REDUCED COST WAS CLOSED.
21	THAT \$350 STUDENT REGISTRATION WAS CLOSED, AND I WAS
22	ABLE TO TALK TO ISSCR AND HAVE THEM AGREE THAT SINCE
23	ANYONE WHO COULD HAVE AFFORDED IT AHEAD OF TIME DID
24	REGISTER, THEY WOULD WITH THIS CONDITION MAKE IT
25	AVAILABLE TO THOSE WHO DID NOT HAVE ANY ACCESS TO

36

1	FUNDS AND WOULD EXTEND THE \$350 STUDENT REGISTRATION
2	PROGRAM FOR THIS LIMITED SPECIFIC GROUP.
3	IT'S AN ISSUE WHERE THE RECOMMENDATION IS
4	THAT WE TRY AND UTILIZE IT ON THIS BASIS. IT WILL
5	EXPAND SIGNIFICANTLY THOSE WHO CAN ATTEND, AND WE DO
6	REALIZE THAT SOME WHO REGISTERED EARLIER ARE MAKING
7	SOME SACRIFICES THEMSELVES.
8	DR. PENHOET: RELATED QUESTION. IF MORE
9	STUDENTS AND POST DOCS, ETC., APPLY FOR THESE
10	MONIES, THEN THEY HAVE AVAILABLE FUNDS FROM THIS
11	GRANT THAT WE'RE GOING TO MAKE, WHO WILL MAKE THE
12	DECISION ABOUT WHO GETS TO COME AND WHO DOES NOT GET
13	TO COME? AND WHAT WILL THE CRITERIA BE FOR THE
14	PETITION THEY MAKE?
15	CHAIRMAN KLEIN: IT'S BEEN PROPOSED
16	WELL, FIRST OF ALL, THE FACULTY MEMBER IN CHARGE OF
17	THE PROGRAM OR IN THE CASE OF RESEARCH TEAMS THE PI
18	OR CO-PI IN CHARGE OF THE TEAM IS TO WRITE THIS
19	ONE-PARAGRAPH RECOMMENDATION AND VERIFICATION THAT
20	THEY ARE A PART OF ONE OF THE QUALIFIED CATEGORIES.
21	AND WITH THOSE RECOMMENDATIONS, IT'S ON A FIRST
22	COME, FIRST-SERVED BASIS BY INSTITUTION.
23	NOW, INSTITUTIONS CAN DECIDE THEMSELVES
24	WHICH RECOMMENDATIONS THEY'RE GOING TO SUBMIT. BUT
25	IT IS A FIRST COME, FIRST-SERVED BASIS BY

37

1	INSTITUTION UP TO THE CAP PER INSTITUTION.
2	ARE THERE ADDITIONAL QUESTIONS?
3	DR. LEVIN: ARE YOU SAYING THAT ISSCR
4	WOULD NOT HONOR THIS EXTENSION OF THE \$350
5	REGISTRATION RATE IF WE ADAPTED THIS PROGRAM TO
6	COVER BOTH PEOPLE WHO WERE REGISTERED AND PEOPLE WHO
7	WEREN'T?
8	CHAIRMAN KLEIN: WELL, THAT'S NOT THE
9	BASIS ON WHICH I WAS ABLE TO NEGOTIATE THE
10	EXTENSION, DR. LEVIN. AND I WOULD HAVE TO GO BACK
11	TO THEM TO FIND OUT IF THEY WOULD DO SO, AND WE DO
12	NOT HAVE ANOTHER BOARD MEETING TO CONSIDER THIS IN
13	THE INTERIM.
14	DR. PRIETO: GIVEN THE TIME CONSTRAINTS, I
15	THINK THAT WE WOULD BE ASKING THEM TO GOING BACK
16	TO THEM AND ASKING THEM TO CHANGE THE TERMS OF THE
17	AGREEMENT, AND I DON'T THINK THAT'S PRACTICAL.
18	DR. LEVIN: MY QUESTION WAS JUST COULD
19	WE IF WE VOTED FOR A FRIENDLY AMENDMENT TO EXTEND
20	IT TO PEOPLE WHO HAD ALREADY REGISTERED, WOULD THAT
21	REQUIRE ADDITIONAL ACTION. AND IT SOUNDS LIKE THE
22	ANSWER IS YES. SO WE DON'T HAVE THAT OPTION.
23	CHAIRMAN KLEIN: RIGHT. ALL RIGHT. IS
24	THERE ARE THERE COMMENTS FROM ANY MEMBERS OF THE
25	PUBLIC?

38

1	MS. KING: YES. WE HAVE ONE FROM A MEMBER
2	OF THE PUBLIC. WE HAVE A COMMENT HERE IN SAN
3	FRANCISCO FROM PRESIDENT ALAN TROUNSON.
4	CHAIRMAN KLEIN: DR. TROUNSON, I WAS
5	IMMEDIATELY GOING TO CALL ON YOU, BUT PLEASE.
6	DR. TROUNSON: THIS IS A VERY INTERESTING
7	PROPOSAL, AND IT'S REALLY COME FROM THE CHAIRMAN
8	ORIGINALLY. I THINK IT WILL PRODUCE SOME ISSUES OF
9	PARITY. I THINK IT'S JUST IDENTIFIED. BUT THEY'RE
10	GOING TO HAVE TO LIVE WITH THAT BECAUSE ISSCR ARE
11	GOING TO MANAGE THESE FUNDS AND AS SUCH WILL NOT
12	WANT TO REENTER ANY KIND OF NEGOTIATIONS WITH PEOPLE
13	WHO HAVE ALREADY REGISTERED. I THINK IT WOULD BE
14	FAIR TO SAY THAT MANAGEMENT WAS KIND OF LUKE WARM TO
15	THIS, AND I'M REPRESENTING VIEWS BROADLY ACROSS THE
16	SCIENCE GROUP RATHER THAN ANY INDIVIDUAL, THAT
17	NORMALLY WHAT HAPPENS IS THAT THE BEST PEOPLE, THE
18	BEST SCIENTISTS AND THE ONES THAT HAVE PROGRESSED
19	THE BEST GET THE OPPORTUNITIES TO GO TO THESE
20	MEETINGS. THOSE THAT ARE VERY EARLY DON'T REALLY
21	BENEFIT VERY MUCH FROM THIS EXPOSURE.
22	THEY NEED TO BE IN THEIR STUDIES FOR AT
23	LEAST A YEAR OR A YEAR AND A HALF BEFORE THERE'S
24	REALLY ANY BENEFIT. AND WE ARE PROBABLY EXTENDING
25	THOSE BENEFITS DOWN TO THESE PEOPLE.

39

1	SO THE RETURN ON A QUARTER OF A MILLION
2	DOLLARS IN RESPECT TO AT LEAST SOME OF MANAGEMENT'S
3	STAFF IS RATHER DUBIOUS, BUT IT IS VERY CLEAR THAT
4	THERE'S A BENEFIT FOR ISSCR. LET ME BE CLEAR ABOUT
5	THAT. THEY WOULD HAVE THEY WOULD STRONGLY
6	BENEFIT FROM THIS. SO THERE'S GOOD REASON WHY
7	THEY'D WANT TO DO IT.
8	BUT I PERSONALLY AM SUPPORTIVE OF THIS,
9	BUT I REALLY WANTED TO BRING MANAGEMENT'S LUKE WARM
10	FEELING TO THE BOARD. IT WOULDN'T BE FAIR IF I
11	HADN'T DONE THAT BECAUSE I THINK THERE ARE THIS
12	IS AN UNUSUAL, THIS IS A VERY UNUSUAL MOVE VERY LATE
13	IN PRACTICE AND WILL BRING SOME ISSUES FROM SOME OF
14	OUR SENIOR RESEARCHERS THAT IT WASN'T SORT OF
15	PRETHOUGHT OF INITIALLY.
16	CHAIRMAN KLEIN: AND I THINK IN THE
17	INTEREST OF FULLY DISCUSSING IT, I APPRECIATE YOUR
18	COMMENTS. I TOOK THIS CONCERN FROM OUR SOME OF
19	OUR SCIENTIFIC STAFF TO THE ISSCR, SPECIFICALLY
20	TALKED TO IRV WEISSMAN, WHO IS THE PRESIDENT OF THE
21	ISSCR ABOUT THIS. AND HIS VIEW WAS THAT THERE WERE
22	TREMENDOUS PEOPLE ON THE RESEARCH TEAMS THAT HE WAS
23	AWARE OF WHERE THEY WERE VERY JUNIOR ON THE TEAM,
24	DID NOT HAVE ANY BUDGET ALLOCATION FOR TRAVEL AND
25	CONFERENCES, OR IT WAS EXTREMELY LIMITED AND HAD

40

1	EXHAUSTED IT BY COMMITMENT TO A VERY NARROW
2	CONFERENCE OR SPECIALIZED CONFERENCE THAT WAS
3	DIRECTLY ON POINT WITH THEIR RESEARCH.
4	BUT HE THOUGHT THAT THEY WOULD BENEFIT
5	HUGELY FROM GOING TO THIS TYPE OF CONFERENCE. AND
6	FROM OTHER RESEARCH PEOPLE HE TALKED TO, HE THOUGHT
7	THERE WAS A GREAT DEAL OF ENTHUSIASM FOR BONDING
8	THIS. HE BELIEVED IT WOULD REALLY HELP THEM
9	CONTINUE TO RECRUIT AND HOLD THE BEST TALENT
10	POSSIBLE WHO WERE JUNIOR IN THESE TEAMS BY GIVING
11	THEM AN EXPOSURE TO THE BROAD SCOPE OF THE FIELD.
12	SO I TOOK HIS COMMENT SERIOUSLY, TRIED TO
13	FOLLOW UP ON IT, AND DR. WEISSMAN HAS A VERY BROAD
14	SPECTRUM VIEW OF FIELD, AND HIS INPUT WOULD BE
15	VALUABLE IN THE PROCESS.
16	MS. KING: AND WE HAVE TWO MINUTES UNTIL
17	WE'RE GOING TO LOSE OUR QUORUM.
18	CHAIRMAN KLEIN: OKAY. DO WE HAVE MORE
19	BOARD COMMENTS?
20	MR. SHESTACK: LET'S GO.
21	CHAIRMAN KLEIN: OKAY. CALL THE QUESTION.
22	MELISSA.
23	MS. KING: I BELIEVE THAT YOU ALREADY
24	ASKED FOR PUBLIC COMMENT, BUT IT'S BEING SUGGESTED
25	THAT MAYBE YOU SHOULD ASK FOR IT AGAIN.
	41
	41

-	
1	CHAIRMAN KLEIN: ALL RIGHT. VERY QUICKLY,
2	IF THERE ARE PUBLIC COMMENTS.
3	MS. KING: SEEING NONE, I'LL BEGIN THE
4	ROLE.
5	RICARDO AZZIZ.
6	DR. AZZIZ: YES.
7	MS. KING: ROBERT BIRGENEAU.
8	DR. BIRGENEAU: YES.
9	MS. KING: FLOYD BLOOM.
10	DR. BLOOM: YES.
11	MS. KING: WILLIAM BRODY.
12	DR. BRODY: YES.
13	MS. KING: JACOB LEVIN.
14	DR. LEVIN: YES.
15	MS. KING: LEEZA GIBBONS.
16	MS. GIBBONS: YES.
17	MS. KING: BOB KLEIN.
18	CHAIRMAN KLEIN: YES.
19	MS. KING: GERALD LEVEY.
20	DR. LEVEY: YES.
21	MS. KING: TED LOVE.
22	DR. LOVE: YES.
23	MS. KING: ED PENHOET.
24	DR. PENHOET: YES.
25	MS. KING: FRANCISCO PRIETO.
	42

1	DR. PRIETO: AYE.
2	MS. KING: ROBERT QUINT.
3	DR. QUINT: YES.
4	MS. KING: JEANNIE FONTANA.
5	DR. FONTANA: YES.
6	MS. KING: DUANE ROTH.
7	MR. ROTH: YES.
8	MS. KING: JOAN SAMUELSON.
9	MS. SAMUELSON: YES.
10	MS. KING: DAVID SERRANO-SEWELL.
11	MR. SERRANO-SEWELL: YES.
12	MS. KING: JEFF SHEEHY.
13	MR. SHEEHY: YES.
14	MS. KING: JONATHAN SHESTACK.
15	MR. SHESTACK: YES.
16	MS. KING: AND ART TORRES.
17	MR. TORRES: AYE.
18	MS. KING: AND THAT MOTION CARRIES. AND
19	THANK YOU ALL FOR BEING HERE.
20	MR. SHEEHY: COULD I ASK A QUICK QUESTION?
21	CHAIRMAN KLEIN: YEAH. I WANT TO, JEFF,
22	GET JAMES HARRISON TO GIVE A COMMENT. IN TERMS OF
23	THE PROGRAM FOR PATIENT ADVOCATES TO ATTEND, IS IT
24	MY UNDERSTANDING WE DON'T NEED A SEPARATE
25	APPROPRIATION AT THE BOARD LEVEL TO DO THAT?
	43

1	MR. HARRISON: THAT'S CORRECT. MY
2	UNDERSTANDING IS THAT THAT IS BEING HANDLED
3	ADMINISTRATIVELY.
4	CHAIRMAN KLEIN: OKAY. AND I WOULD LIKE
5	TO LET THE BOARD KNOW THAT FOLLOWING UP ON A
6	PROPOSAL THAT JEFF SHEEHY MADE AT THE ORIGINAL BOARD
7	MEETING WHERE THE ISSCR WAS DISCUSSED, THERE IS A
8	SPECIAL PROGRAM FOR PATIENT ADVOCATES TO ATTEND.
9	HAVING THOSE PATIENT ADVOCATES WHO HAVE SPECIFIC
10	WHO HAVE DEEP BACKGROUND AND INTEREST ATTEND FROM A
11	BROAD SPECTRUM OF DISEASE GROUPS PROVIDES THEM WITH
12	THE QUALITY OF INFORMATION SO THEY CAN REMAIN AS
13	HIGHLY INFORMED REPRESENTATIVES AND PUBLIC
14	DISCUSSANTS OF THE TOPIC, AND WE ARE FOLLOWING THAT
15	UP ON A PROGRAM THAT WE HAD DISCUSSED AS RECENTLY AS
16	THIS WEEKEND AND YESTERDAY.
17	AND JEFF, I'M GOING TO BE TALKING TO YOU
18	ON THE IMPLEMENTATION OF THAT.
19	MS. KING: JUST TO CLARIFY, CHAIRMAN
20	KLEIN, MAYBE YOU WANT TO
21	CHAIRMAN KLEIN: I WOULD JUST SAY THAT IT
22	WOULD FOLLOW THE SAME PARAMETERS AS THE
23	REIMBURSEMENTS HERE, BUT A MUCH MORE LIMITED
24	PROGRAM. IT WOULD MAXIMALLY INVOLVE ABOUT A HUNDRED
25	PATIENT ADVOCATES FROM AROUND THE STATE. I WOULD
	44

1	EXPECT MORE IN THE RANGE OF 50 TO 70 THAT WOULD
2	ACTUALLY PARTICIPATE, BUT A GOOD DISTRIBUTION ACROSS
3	ALL DISEASE GROUPS IS THE INTENT.
4	MR. SHEEHY: THANK YOU, BOB. THAT REALLY
5	WAS MY QUESTION BECAUSE I HAD HAD A SPECIFIC
6	COMMITMENT FROM THE VICE PRESIDENT OF THE AGENCY
7	THAT WE WOULD IMPLEMENT SUCH A PROGRAM LAST SUMMER
8	WHEN WE VOTED THROUGH FUNDS TO SUPPORT THE ISSCR
9	COMING TO CALIFORNIA. AND WE SPECIFICALLY DISCUSSED
10	ABOUT A PROGRAM, A MODEL ON SOME OF THE THINGS THAT
11	HAPPENED IN HIV. THERE ARE VARIOUS CONFERENCES
12	WHERE PATIENT ADVOCATES ARE PROVIDING SCHOLARSHIPS
13	AND SUPPORT TO ATTEND CONFERENCES. IT JUST SEEMED
14	VERY REASONABLE TO SUPPORT THE FOLKS AROUND
15	CALIFORNIA WHO HAD AN INTEREST IN OUR RESEARCH WHO
16	BASICALLY THROUGH THEIR HARD WORK ON PROP 71 MADE
17	CIRM AND ALL OF OUR ROLES HERE POSSIBLE. SO THANK
18	YOU FOR MOVING FORWARD WITH THIS AND PAYING
19	ATTENTION TO THIS. AND I'M GLAD WE DON'T NEED ANY
20	FURTHER BOARD ACTION ON THIS. THANK YOU.
21	CHAIRMAN KLEIN: OKAY. I THINK, MR.
22	HARRISON, CAN WE THANK THE BOARD?
23	MR. HARRISON: WE SURE CAN.
24	CHAIRMAN KLEIN: WE THANK THE BOARD AND WE
25	THANK THE STAFF FOR THEIR TREMENDOUS COMMITMENT, AND
	45

1	WE THANK AGAIN THE LEADERSHIP OF ART TORRES AND
2	DUANE ROTH IN MOVING US FORWARD HERE. AND WE THANK
3	THE LEGISLATURE FOR THEIR COLLABORATION WITH US ON
4	THESE PROVISIONS.
5	MS. KING: THANKS EVERYBODY.
6	(THE MEETING WAS THEN ADJOURNED AT
7	9:05 A.M.)
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
	46
	1072 BRISTOL STREET, COSTA MESA, CALIFORNIA 92626

1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON MAY 25, 2010, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTER'S REPORTING SERVICE 1072 BRISTOL STREET SUITE 100 COSTA MESA, CALIFORNIA (714) 444-4100